Key points from article :
BioAge Labs has teamed up with Age Labs to explore ways to extend healthy lifespan by examining the biological underpinnings of ageing. BioAge, a biotechnology company, focuses on creating drugs that target ageing’s molecular causes, while Age Labs, a diagnostic firm, specializes in biomarkers that can detect age-related diseases early.
The partnership leverages data from the Nord-Trøndelag Health Study (HUNT) biobank, which holds health records and biological samples—such as blood—from over 100,000 northern Europeans collected over more than 25 years. By using multi-omics analyses and machine learning, BioAge aims to identify molecular mechanisms that promote healthy longevity. The partnership grants BioAge exclusive rights to data generated for drug discovery, providing a unique opportunity to target new pathways in ageing.
BioAge's discovery platform, powered by machine learning, has already led to potential treatments for age-related diseases. With this extensive biobank data, BioAge expects to accelerate new discoveries in ageing and expand its drug portfolio.
Age Labs will use its EPIPHANY platform to develop biomarkers for early disease detection and to predict drug responses, focusing on applications in diagnostics and clinical trials. COO Eric Morgen emphasizes that the health records linked to the biobank data allow researchers to identify ageing pathways most connected to longevity outcomes.
BioAge also holds partnerships with biobanks across various regions, with data covering participants for up to 45 years. This collaboration with Age Labs marks a significant step in BioAge’s efforts to expand its understanding of human ageing, aiming to discover new ways to enhance healthspan and manage age-related diseases.
